Patents by Inventor Karim DABBAGH

Karim DABBAGH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 12661383
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: June 23, 2026
    Assignee: Genevive, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 12371456
    Abstract: The disclosure related to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: July 29, 2025
    Assignee: Genevive, Inc.
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 12186364
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 7, 2025
    Assignee: Genevive, Inc.
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • Microbially derived peptides and proteins for immunotherapy
    Patent number: 12168676
    Abstract: The disclosure provides therapeutic peptides and pharmaceutical compositions comprising the peptides, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system to mitigate disease.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: December 17, 2024
    Assignee: Genevive, Inc.
    Inventors: Yuliya Katlinskaya, Helena Kiefel, Kareem L. Graham, Todd Z. DeSantis, Sunit Jain, Andrew W. Han, Karim Dabbagh
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 12168677
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: December 17, 2024
    Assignee: Genevive, Inc.
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • PEPTIDES FOR IMMUNOTHERAPY
    Publication number: 20240317816
    Abstract: The disclosure provides peptides, pharmaceutical compositions, and methods of producing thereof. Such peptides can be useful, for example, in treating various human diseases such as immunological diseases or cancers. In some embodiments, the peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 26, 2024
    Inventors: Helena Kiefel, Dhwani Haria, Michi Izumi Willcoxon, Kyle Roskamp, Toshihiko Takeuchi, Karim Dabbagh
  • ROSEBURIA HOMINIS, EUBACTERIUM ELIGENS, AND COMBINATIONS THEREOF AS BIOTHERAPEUTICS
    Publication number: 20240115625
    Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacteria Rosburia hominis and Eubacterium eligens and their uses in treating metabolic-related diseases or disorders.
    Type: Application
    Filed: February 21, 2023
    Publication date: April 11, 2024
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Mitsuko Lynn Yamamoto, Todd Zachary DeSantis, Karim Dabbagh
  • PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
    Publication number: 20240076323
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 7, 2024
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
    Publication number: 20240066095
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: April 24, 2023
    Publication date: February 29, 2024
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
    Publication number: 20240043477
    Abstract: The disclosure related to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: December 9, 2022
    Publication date: February 8, 2024
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 11666627
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 6, 2023
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary Desantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
    Publication number: 20220257703
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: March 10, 2022
    Publication date: August 18, 2022
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • as a biotherapeutic
    Patent number: 11389487
    Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Streptococcus australis and their uses in treating metabolic-related diseases or disorder.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: July 19, 2022
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Bernat Baeza Raja, Shoko Kawana, Mitsuko Lynn Yamamoto, Karim Dabbagh, Todd Zachary DeSantis
  • PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
    Publication number: 20220185849
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 16, 2022
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • as a biotherapeutic
    Patent number: 11344584
    Abstract: The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Gemella sanguinis and their uses in treating metabolic-related diseases or disorder.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 31, 2022
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Bernat Baeza Raja, Shoko Kawana, Mitsuko Lynn Yamamoto, Karim Dabbagh, Todd Zachary DeSantis
  • PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
    Publication number: 20220106365
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: November 15, 2021
    Publication date: April 7, 2022
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • MICROBIALLY DERIVED PEPTIDES AND PROTEINS FOR IMMUNOTHERAPY
    Publication number: 20220089653
    Abstract: The disclosure provides therapeutic peptides and pharmaceutical compositions comprising the peptides, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system to mitigate disease.
    Type: Application
    Filed: January 6, 2020
    Publication date: March 24, 2022
    Inventors: Yuliya Katlinskaya, Helena Kiefel, Kareem L. Graham, Todd Z. DeSantis, Sunit Jain, Andrew W. Han, Karim Dabbagh
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 11273198
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 15, 2022
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 11207376
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: December 28, 2021
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary Desantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 11174293
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 16, 2021
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh